| Abbott 'highlights strong global citizenship performance' | Posted on 10/05/2007 in Pharmaceutical Company Restructures Abbott has released its global citizen report for 2006, with the publication outlining its performance in financial, social and environmental spheres. For the year, the company has reported a "strong" performance in the area of corporate social responsibility.
The report - Generations - explores a number of areas involved in the notion of global citizenship, from compliance and governance to the firm's policy on the environment, health and safety concerns and its staff worldwide.
Also included is an examination of other concerns central to the theme of global citizenship, including the widening of access to healthcare products manufactured by the firm.
These efforts have included improved design of pharmaceutical product labels, the expansion of tiered pricing for Kaletra/Aluvia, approximately $300 million (150 million pounds) investment in humanitarian efforts and increased openness in clinical trials.
Miles D White, chairman and chief executive officer of Abbott, said: "Global citizenship is fundamental to earning and deepening the trust of the people we serve - and an integral part of our commitment to improve lives."
He added that the concept of global citizenship cannot be set apart from the rest of the business of Abbott, with such ideals essential to ensure corporate discipline and competitive health throughout the business.
Last month, Abbott reported sales of $5.3 billion for the first quarter of the 2007 fiscal year, a 15.5 per cent rise on the same quarter last year.Other news stories from 10/05/2007
Read more in the Zenopa News Archive
How this news is generated
|  |
|
